Citations

Clear

1526 citation(s) found for "Sun, Yu".

Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients
Hu, Rou-Mu, Tester, David J. , Li, Ryan , Sun, Tianyu , Peterson, Blaise Z., Ackerman, Michael J. , Makielski, Jonathan C., Tan, Bi-Hua, Li, Ryan, Tan, Bi‐Hua

Mayo Clinic

Channels | July 7, 2018 | Volume: 12 | Issue: 1 | Pages: 176-186

10.1080/19336950.2018.1475794 | PMID 29983085 Get It

Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study
Kálmán, János , Papiol, Sergi , Forstner, Andreas J. , Heilbronner, Urs , Degenhardt, Franziska , Adli, Mazda , Adorjan, Kristina , Akula, Nirmala , Alda, Martin , Anderson‐Schmidt, Heike , Andlauer, Till F. M. , Anghelescu, Ion‐George , Ardau, Raffaella , Arias, Bárbara , Arolt, Volker , Aubry, Jean‐Michel , Bartholdi, Kim, Bauer, Michael , Benabarre, Antonio , Bengesser, Susanne , Bhattacharjee, Abesh Kumar, Birner, Armin , Brichant‐Petitjean, Clara, Cervantes, Pablo , Chillotti, Caterina , Cichon, Sven , Clark, Scott R. , Comes, Ashley L. , Cruceanu, Cristiana , Czerski, Piotr M. , Zompo, Maria Del , Dietrich, Detlef E. , Étain, Bruno , Ethofer, Thomas , Falkai, Peter , Fallgatter, Andreas J. , Figge, Christian, Flatau, Laura , Folkerts, Here, Frisén, Louise , Frye, Mark A. , Fullerton, Janice M. , Gade, Katrin , Gard, Sébastien, Grigoroiu‐Serbânescu, Maria , Gryaznova, Anna, Hake, Maria, Jäger, Markus , Jamain, Stéphane , Jiménez, Esther , Juckel, Georg , Kahn, Jean‐Pierre, Kassem, Layla, Kittel‐Schneider, Sarah , Kliwicki, Sebastian , Klohn‐Sagatholislam, Farah, Köller, Manfred , Konrad, Carsten , Lackner, Nina , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Leckband, Susan G. , Maj, Mario , Manchia, Mirko , Martinsson, Lina , McCarthy, Michael J. , McMahon, Francis J. , Mitjans, Marina , Mondimore, Francis M. , Nieratschker, Vanessa , Novák, Tomáš , Ösby, Urban, Potash, James B. , Reich‐Erkelenz, Daniela , Reif, Andreas , Reimer, Jens , Reininghaus, Eva Z. , Reitt, Markus , Ripke, Stephan , Schalling, Martin , Scherk, Harald, Schmauß, Max, Schubert, Klaus Oliver , Schulte, Eva C. , Schulz, Sybille, Senner, Fanny , Severino, Giovanni , Shekhtman, Tatyana , Shilling, Paul D. , Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Stegmaier, Sophia, Stierl, Sebastian, Stopková, Pavla , Thiel, Andreas , Tighe, Sarah K., Tortorella, Alfonso , Turecki, Gustavo , Vieta, Eduard , Veeh, Julia, Hagen, Martin von, Wigand, Moritz E. , Wiltfang, Jens , Zandi, Peter P. , Zimmermann, Jörg , Heilbronner, Maria , Etain, B , Vieta, E , Cichon, Sven , Alda, Martin , Ripke, Stephan , Fullerton, Janice M , Strohmaier, Jana , Aubry, Jean‐Michel , Backlund, Lena , Baune, Bernhard , Becker, Thomas M , Bellivier, Frank , Biernacka, Joanna M. , Budde, Monika , Colom, Francesc , Dannlowski, Udo , Dayer, Alexandre G. , DePaulo, J Raymond , Garnham, Julie , Goes, Fernando , Gryaznova, Anna, Hauser, Joanna , Herms, Stefan , Hoffmann, Per , Hou, Liping , Kelsoe, John R , Klöhn-Sagatholislam, Farahnaz, König, Barbara , Lang, Fabian U. , McElroy, Susan L. , Mitchell, Philip B , Monteleone, Palmiero , Nievergelt, Caroline M , Pfennig, Andrea , Reininghaus, Eva , Rouleau, Guy Armand , Rybakowski, Janusz K , Schofield, Peter R. , Spitzer, Carsten , Squassina, Alessio , Witt, Stephanie H. , Wright, A. Jordan , Nöthen, Markus M. , Rietschel, Marcella , Schulze, Thomas , Papiol, Sergi , Heilbronner, Urs , Cruceanu, Cristiana , Czerski, Piotr , Jamain, Stéphane , Grigoroiu-Serbanescu, Maria , Kalman, Janos , Schulte, Eva , Wiltfang, Jens , Andlauer, Till , Kittel-Schneider, Sarah , Lavebratt, Catharina , Leboyer, Marion , Tortorella, Alfonso , McCarthy, Michael , Novak, Tomas , Reif, Andreas , Stopkova, Pavla , Turecki, Gustavo , McMahon, Francis , Arias, Bárbara , Schubert, Klaus Oliver , Mitjans, Marina , Manchia, Mirko

Mayo Clinic

Bipolar Disorders | June 28, 2018 | Volume: 21 | Issue: 1 | Pages: 68-75

10.1111/bdi.12659 | PMID 29956436 Get It

Objectives Bipolar disorder (BD) with early disease onset is associated with an unfavorable clinical outcome and constitutes a clinically and biologically homogenous subgroup within the heterogeneous BD spectrum. Previous studies have found an accumulation of early age at onset (AAO) in BD families and have therefore hypothesized that there is a larger genetic contribution to the early‐onset cases than to late onset BD. To investigate the genetic background of this subphenotype, we evaluated whether an increased polygenic burden of BD‐ and schizophrenia (SCZ)‐associated risk variants is associated with an earlier AAO in BD patients. Methods A total of 1995 BD type 1 patients from the Consortium of Lithium Genetics (ConLiGen), PsyCourse and Bonn‐Mannheim samples were genotyped and their BD and SCZ polygenic risk scores (PRSs) were calculated using the summary statistics of the Psychiatric Genomics Consortium as a training data set. AAO was either separated into onset groups of clinical interest (childhood and adolescence [≤18 years] vs adulthood [>18 years]) or considered as a continuous measure. The associations between BD‐ and SCZ‐PRSs and AAO were evaluated with regression models. Results BD‐ and SCZ‐PRSs were not significantly associated with age at disease onset. Results remained the same when analyses were stratified by site of recruitment. Conclusions The current study is the largest conducted so far to investigate the association between the cumulative BD and SCZ polygenic risk and AAO in BD patients. The reported negative results suggest that such a polygenic influence, if there is any, is not large, and highlight the importance of conducting further, larger scale studies to obtain more information on the genetic architecture of this clinically relevant phenotype.
Pump Position Impacts HeartMate II Left Ventricular Assist Device Thrombosis
Ransom, John , Maltais, Simon, Sun, Benjamin , Entwistle, John W. , Bailey, Stephen, John, Ranjit , Klodell, C.T., Gregorič, Igor D. , Sheridan, Brett C. , Chuang, Joyce, Farrar, David J. , Sundareswaran, Kartik S., Adamson, Robert, Kılıç, Ahmet

Mayo Clinic

ASAIO Journal | June 26, 2018 | Volume: 65 | Issue: 3 | Pages: 227-232

10.1097/mat.0000000000000840 | PMID 29952801 Get It

The PREVENtion of HeartMate II pump Thrombosis through clinical management (PREVENT) study was a multicenter, prospective investigation to evaluate the rate of pump thrombosis (PT) with adoption of a uniform set of surgical and medical practices for left ventricular assist device implantation. We sought to quantify pump position at baseline and retrospectively define a pump position associated with poor clinical outcomes. Chest x-rays at baseline were prospectively obtained per protocol. Pump pocket depth, inflow cannula (IC) angle relative to the pump, and IC angle relative to the vertical were measured. Pumps falling in the tail-ends of the IC angle and pump pocket depth distributions were categorized as having an extreme pump position within the PREVENT study. Patients with extreme pump position had a significantly higher risk of confirmed and suspected PT, hemolysis, and elevated lactate dehydrogenase. In a multivariable analysis of survival free of confirmed PT, extreme pump position was an independent risk factor (hazard ratio = 3.6; 95% confidence interval = 1.5–8.9; p = 0.006) when adjusting for differences in pump speed and anticoagulation level. Our analysis shows that HeartMate II pump position at implant can significantly impact event-free survival and the incidence of adverse events at 6 months.
ARNT/HIF‐1β links high‐risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma
Liu, Yingmin , Yi-cheng, LU , Liu, Xiaobo , Liu, Xuelian , Ye, Long , Sun, Yue , Wang, Xue , Yang, Pei‐Yu , Gao, Sujun , Kumar, Shaji , Jin, Fengyan , Dai, Yun , Li, Wei , Dai, Yun , Wu, Chuan, Yang, Ting , Yang, Yanping , Li, Qingchao , Yu, Xiaoyuan

Mayo Clinic

Cancer Medicine | June 21, 2018 | Volume: 7 | Issue: 8 | Pages: 3899-3911

10.1002/cam4.1596 | PMID 29926531 Get It

Abstract1q21 gain is a common cytogenetic abnormality featuring high‐risk multiple myeloma (HRMM). However, the molecular mechanism underlying the adverse prognostic effect of 1q21 gain remains largely unclear. Here, we report that ARNT/HIF‐1β, a 1q21 gene, is highly expressed in HRMM and induced by microenvironmental hypoxia, which confers drug resistance and correlates with inferior outcome. Analysis of the gene expression profile database revealed that ARNT expression was upregulated in MM and increased with disease progression or in HRMM subtypes (particularly 1q21 gain), while correlated to shorter overall survival. In a cohort of 40 MM patients, qPCR further validated that ARNT expression was higher in MM patients than normal donors. MM cells carrying 1q21 gain or acquired drug resistance displayed a robust increase in HIF‐1β protein level. Hypoxia induced HIF‐1β expression via a NF‐κB‐dependent process. Notably, HIF‐1β overexpression impaired bortezomib sensitivity, whereas shRNA knockdown of ARNT reversed hypoxia‐mediated drug resistance. Together, these findings suggest that ARNT/HIF‐1β might represent a novel biomarker for risk stratification and prognosis of HRMM patients, as well as a potential therapeutic target for overcoming 1q21 gain‐ or microenvironment‐mediated and acquired drug resistance in MM.
Very poor long‐term survival in past and more recent studies for relapsed AML patients: The ECOG‐ACRIN experience
Ganzel, Chezi , Sun, Zhuoxin , Cripe, Larry D., Fernández, Hugo F. , Douer, Dan , Rowe, Jacob M. , Paietta, Elisabeth , Wiernik, Peter H. , Bennett, John M. , Litzow, Mark R. , Luger, Selina M. , Tallman, Martin S. , O'Connell, Michael J, Ketterling, Rhett P. , O’Connell, Michael J. , Lazarus, Hillard M.

Mayo Clinic

American Journal of Hematology | June 15, 2018 | Volume: 93 | Issue: 8 | Pages: 1074-1081

10.1002/ajh.25162 | PMID 29905379 Get It

AbstractThis study examines the long‐term OS of relapsed AML patients who were enrolled to 9 successive ECOG‐ACRIN trials for newly diagnosed AML, during 1984‐2008. The objectives were to examine whether there is a trend of improvement in the survival of relapsed AML patients in the more recent studies and to search for prognostic factors that are associated with long‐term OS after relapse. A total of 3012 patients were enrolled, 1779 (59.1%) achieved CR1 and of these, 58.9% relapsed. The median follow‐up was 9.7 years. The median OS from relapse was 0.5 years and the 5‐year OS was 10 (±1)%. These results were similar even for the most recent studies. A multivariate model showed that age, cytogenetics at diagnosis, duration of CR1 and undergoing allogeneic transplantation were significantly associated with OS from relapse. Even among patients who relapsed with better prognostic factors; age < 40 and CR1 > 12 months, there was no significant OS difference between the studies. In conclusion, this large cohort appears to confirm that the survival of AML patients postrelapse continues to be dismal and has not improved during the past quarter of a century.
Effects of Brain-Derived Neurotrophic Factor on MicroRNA Expression Profile in Human Endothelial Progenitor Cells
He, Tongrong , Sun, Ruohan , Katušić, Zvonimir S. , Li, Ying

Mayo Clinic

Cell Transplantation | June 4, 2018 | Volume: 27 | Issue: 6 | Pages: 1005-1009

10.1177/0963689718761658 | PMID 29860902 Get It

The mechanisms underlying proangiogenic function of brain-derived neurotrophic factor (BDNF) are not fully understood. The current study was designed to explore the microRNA (miRNA) profile in human early endothelial progenitor cells (EPCs, also referred to as CFU-Hill cells) treated with BDNF. Treatment of early EPCs with BDNF for 7 d significantly increased the colony formation of outgrowth endothelial cells. BDNF suppressed the expression of miR-4716-5p, miR-3928, miR-433, miR-1294, miR-1539, and miR-19b-1*. In contrast, BDNF significantly increased the levels of miR-432*, miR-4499, miR-3911, miR-1183, miR-4669, miR-636, miR-4717-3p, miR-4298, miR485-5p, and miR-181c. Since miR-433 has been reported to augment hematopoietic cells proliferation and differentiation, we examined the role of miR-433 in regenerative effects of BDNF. BDNF stimulated the protein expression of guanylate-binding protein 2 via the suppression of miR-433. However, the knockdown of miR-433 was not sufficient to significantly increase the number of outgrowth endothelial cell colonies, suggesting that modulation of miR-433 alone does not stimulate regenerative capacity of EPCs. In aggregate, our results also suggest that the effect of BDNF on regenerative function of EPCs may depend on complex changes in the expression of microRNAs.
Anti‐viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus‐related hepatocellular carcinoma: real‐world east and west experience
Chen, Vincent , Yeh, Ming-Lun, Le, An K. , Jun, Mi Jung, Saeed, Waqar Khalid , Yang, Ju Dong , Huang, Chung‐Feng , Lee, H. Y., Tsai, Pei‐Chien , Giama, Nasra H., Kim, N. G., Nguyen, Phuong , Dang, Hansen , Ali, Hamdi A. , Zhang, N., Chuang, Wan‐Long , Roberts, Lewis R. , Yu, Ming‐Lung , Nguyen, Mindie H. , Chen, V L , Huang, C-F , Jun, D W , Yu, M-L , Nguyen, Mindie H , Roberts, Lewis R , Yeh, Ming-Lun , Yang, Ju Dong , Lee, M.‐H., Huang, Jee‐Fu , Dai, Chia-Yen , Lim, Young‐Suk

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 24, 2018 | Volume: 48 | Issue: 1 | Pages: 44-54

10.1111/apt.14801 | PMID 29797518 Get It

SummaryBackgroundHepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) worldwide. It remains incompletely understood in the real world how anti‐viral therapy affects survival after HCC diagnosis.MethodsThis was an international multicentre cohort study of 2518 HBV‐related HCC cases diagnosed between 2000 and 2015. Cox proportional hazards models were utilised to estimate hazard ratios (HR) with 95% (CI) for anti‐viral therapy and cirrhosis on patients' risk of death.ResultsApproximately, 48% of patients received anti‐viral therapy at any time, but only 17% were on therapy at HCC diagnosis (38% at US centres, 11% at Asian centres). Anti‐viral therapy would have been indicated for >60% of the patients not on anti‐viral therapy based on American criteria. Patients with cirrhosis had lower 5‐year survival (34% vs 46%; P < 0.001) while patients receiving anti‐viral therapy had increased 5‐year survival compared to untreated patients (42% vs 25% with cirrhosis and 58% vs 36% without cirrhosis; P < 0.001 for both). Similar findings were seen for other patient subgroups by cancer stages and cancer treatment types. Anti‐viral therapy was associated with a decrease in risk of death, whether started before or after HCC diagnosis (adjusted HR 0.62 and 0.79, respectively; P < 0.001).ConclusionsAnti‐viral therapy improved overall survival in patients with HBV‐related HCC across cancer stages and treatment types but was underutilised at both US and Asia centres. Expanded use of anti‐viral therapy in HBV‐related HCC and better linkage‐to‐care for HBV patients are needed.
Downregulation of BK channel function and protein expression in coronary arteriolar smooth muscle cells of type 2 diabetic patients
Lü, Tong , Chai, Qiang , Jiao, Guoqing, Wang, Xiao-Li, Sun, Xiaojing , Furuseth, Jonathan D, Stulak, John M., Daly, Richard C. , Greason, Kevin L. , Cha, Yong‐Mei , Lee, Hon-Chi, Lu, Tong , Chai, Qiang, Wang, Xiao-Li

Mayo Clinic

Cardiovascular Research | May 22, 2018 | Volume: 115 | Issue: 1 | Pages: 145-153

10.1093/cvr/cvy137 | PMID 29850792 Get It

Abstract Aims Type 2 diabetes (T2D) is strongly associated with cardiovascular morbidity and mortality in patients. Vascular large conductance Ca2+-activated potassium (BK) channels, composed of four pore-forming α subunits (BK-α), and four regulatory β1 subunits (BK-β1), are densely expressed in coronary arterial smooth muscle cells (SMCs) and play an important role in regulating vascular tone and myocardial perfusion. However, the role of BK channels in coronary microvascular dysfunction of human subjects with diabetes is unclear. In this study, we examined BK channel function and protein expression, and BK channel-mediated vasodilation in freshly isolated coronary arterioles from T2D patients. Methods and results Atrial tissues were obtained from 16 patients with T2D and 25 matched non-diabetic subjects during cardiopulmonary bypass procedure. Microvessel videomicroscopy and immunoblot analysis were performed in freshly dissected coronary arterioles and inside-out single BK channel currents was recorded in enzymatically isolated coronary arteriolar SMCs. We found that BK channel sensitivity to physiological Ca2+ concentration and voltage was downregulated in the coronary arteriolar SMCs of diabetic patients, compared with non-diabetic controls. BK channel kinetics analysis revealed that there was significant shortening of the mean open time and prolongation of the mean closed time in diabetic patients, resulting in a remarkable reduction of the channel open probability. Functional studies showed that BK channel activation by dehydrosoyasaponin-1 was diminished and that BK channel-mediated vasodilation in response to shear stress was impaired in diabetic coronary arterioles. Immunoblot experiments confirmed that the protein expressions of BK-α and BK-β1 subunits were significantly downregulated, but the ratio of BK-α/BK-β1 was unchanged in the coronary arterioles of T2D patients. Conclusions Our results demonstrated for the first time that BK channel function and BK channel-mediated vasodilation were abnormal in the coronary microvasculature of diabetic patients, due to decreased protein expression and altered intrinsic properties of BK channels.
Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND‐HF
Verma, Amanda , Sun, Jie‐Lena , Schulte, Phillip J. , Armstrong, Paul W. , O'Conner, Christopher M., Mentz, Robert J. , Verma, Amanda K , Hernandez, Adrian F. , Teerlink, John R , Ezekowitz, Justin A. , Voors, Adriaan A. , Starling, Randall C. , Mentz, Robert J

Mayo Clinic

Clinical Cardiology | May 21, 2018 | Volume: 41 | Issue: 7 | Pages: 945-952

10.1002/clc.22981 | PMID 29781109 Get It

BackgroundHeart rate and systolic blood pressure (SBP) are prognostic markers in heart failure (HF) with reduced ejection fraction (HFrEF). Their combination in rate pressure product (RPP) as well as their role in heart failure with preserved ejection fraction (HFpEF) remains unclear.HypothesisRPP and its components are associated with HFpEF outcomes.MethodsWe performed an analysis of Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND‐HF; http://www.clinicaltrials.gov NCT00475852), which studied 7141 patients with acute HF. HFpEF was defined as left ventricular ejection fraction ≥40%. Outcomes were assessed by baseline heart rate, SBP, and RPP, as well as the change of these variables using adjusted Cox models.ResultsAfter multivariable adjustment, in‐hospital change but not baseline heart rate, SBP, and RPP were associated with 30‐day mortality/HF hospitalization (hazard ratio [HR]: 1.17 per 5‐bpm heart rate, HR: 1.20 per 10‐mm Hg SBP, and HR: 1.02 per 100 bpm × mm Hg RPP; all P < 0.05). Baseline SBP was associated with 180‐day mortality (HR: 0.88 per 10‐mm Hg, P = 0.028). Though change in RPP was associated with 30‐day mortality/HF hospitalization, the RPP baseline variable did not provide additional associative information with regard to outcomes when compared with assessment of baseline heart rate and SBP variables alone.ConclusionsAn increase in heart rate and SBP from baseline to discharge was associated with increased 30‐day mortality/HF hospitalization in HFpEF patients with acute exacerbation. These findings suggest value in monitoring the trend of vital signs during HFpEF hospitalization.
Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials
Iwatsubo, Takeshi , Iwata, Atsushi , Suzuki, Kazushi , Ihara, Ryoko , Arai, Hiroyuki , Ishii, Kenji , Senda, Michio , Kuwano, Ryozo, Initiative, Japanese Alzheimer's Disease Neuroimaging, Sun, Chung‐Kai , Petersen, Ronald C. , Weiner, Michael W. , Aisen, Paul , Donohue, Michael , Initiative, Alzheimer's Disease Neuroimaging, Shoji, Mikio , Ito, Kengo , Ikeuchi, Takeshi , Matsuda, Hiroshi , Initiative, Japanese Alzheimer's Disease Neuroimaging, Beckett, Laurel , Initiative, Alzheimer's Disease Neuroimaging, Donohue, Michael C

Mayo Clinic

Alzheimer's & Dementia | May 9, 2018 | Volume: 14 | Issue: 8 | Pages: 1077-1087

10.1016/j.jalz.2018.03.009 | PMID 29753531 Get It

AbstractIntroductionWe conducted Japanese Alzheimer's Disease Neuroimaging Initiative (J‐ADNI) and compared the basic characteristics and progression profiles with those of ADNI in North America.MethodsA total of 537 Japanese subjects with normal cognition, late amnestic mild cognitive impairment (LMCI), or mild Alzheimer's disease (AD) were enrolled using the same criteria as ADNI. Rates of changes in representative cognitive or functional measures were compared for amyloid positron emission tomography‐ or cerebrospinal fluid amyloid β(1–42)‐positive LMCI and mild AD between J‐ADNI and ADNI.ResultsAmyloid positivity rates were significantly higher in normal cognition of ADNI but at similar levels in LMCI and mild AD between J‐ADNI and ADNI. Profiles of decline in cognitive or functional measures in amyloid‐positive LMCI in J‐ADNI (n = 75) and ADNI (n = 269) were remarkably similar, whereas those in mild AD were milder in J‐ADNI (n = 73) compared with ADNI (n = 230).DiscussionThese results support the feasibility of bridging of clinical trials in the prodromal stage of AD between Asia and western countries.